OCIL/CLEC2d Antibody (402659)

Product Discontinued

OCIL/CLEC2d Antibody (402659) Summary

• Specificity: Detects rhOCIL in direct ELISAs and Western blots. Stains human OCIL transfectants but not irrelevant transfectants. In Western blots, shows no cross-reactivity with rhCLEC4D or rmOCILrp1.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse

Applications/Dilutions

• Dilutions:
  • Flow Cytometry

Packaging, Storage & Formulations

• Storage: Store the unopened product at -20 to -70 °C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Do not use past expiration date.
• Buffer: Lyophilized from a 0.2 μm filtered solution in with Trehalose.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OCIL/CLEC2d Antibody (402659)

• CLAXLLT-1
• CLEC2D
• C-type lectin domain family 2 member D
• C-type lectin domain family 2, member D
• C-type lectin related f
• Lectin-like NK cell receptor
• Lectin-like transcript 1
• LLT1
• LLT1Osteoclast inhibitory lectin
• OCIL
• OCILmember D

Background

Human OCIL (osteoclast inhibitory lectin; also LLT1 and CLEC-2D) is a member of the NK cell receptor group of the C-type lectin superfamily. It is a type II transmembrane protein 191 amino acids (aa) in length that contains a C-terminal 132 aa extracellular domain (ECD). Within the ECD lies a C-type lectin domain (aa 75 - 186). There are at least two alternate splice forms of OCIL. Both exhibit splicing in the ECD. One shows a 40 aa substitution for the C-terminal 37 amino acids. A second shows a 3 aa substitution for the C-terminal 72 amino acids. The ECD of human OCIL is 49% and 50% aa identical to the ECD in mouse and rat OCIL ECD, respectively. The molecule is found on hematopoietic cells, osteoblasts and chondrocytes. It binds sulfated GAGs and NKR-P1B and D receptors, and blocks osteoclast formation.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for OCIL/CLEC2d Antibody (MAB3480)(2)

Publications using MAB3480

• Germain C, Meier A, Jensen T, Knapnougel P, Poupon G, Lazzari A, Neisig A, Hakansson K, Dong T, Wagtmann N, Galsgaard ED, Spee P, Braud VM Induction of lectin-like transcript 1 (LLT1) protein cell surface expression by pathogens and interferon-gamma contributes to modulate immune responses. J. Biol. Chem., 2011-09-19;286(44):37964-75. 2011-09-19 [PMID: 21930700] (Neutralization, Human)
• Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells. Int. J. Cancer, 2009-04-01;124(7):1594-604. 2009-04-01 [PMID: 19089914] (Flow Cytometry, Human)

Bioinformatics

• Uniprot:
  • NP_037401()